Pacritinib US FDA Label

• Compound: (16E)-11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaene
• Description: Pacritinib is an azamacrocycle with formula C28H32N4O3. It is a Janus kinase inhibitor and its citrate salt is approved for the treatment of intermediate or high risk, primary or secondary myelofibrosis. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an antineoplastic agent, an apoptosis inducer and an anti-inflammatory agent. It is an azamacrocycle, a member of pyrrolidines, a cyclic ether and a member of benzenes. It is a conjugate base of a pacritinib(1+).